We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing
Read MoreHide Full Article
Organon (OGN - Free Report) closed the most recent trading day at $7.44, moving +2.76% from the previous trading session. This change outpaced the S&P 500's 0.64% gain on the day. Meanwhile, the Dow experienced a rise of 1.23%, and the technology-dominated Nasdaq saw an increase of 0.69%.
Heading into today, shares of the pharmaceutical company had gained 1.4% over the past month, outpacing the Medical sector's gain of 0.63% and the S&P 500's gain of 0.55%.
The investment community will be paying close attention to the earnings performance of Organon in its upcoming release. On that day, Organon is projected to report earnings of $0.74 per share, which would represent a year-over-year decline of 17.78%. Our most recent consensus estimate is calling for quarterly revenue of $1.53 billion, down 3.84% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.78 per share and a revenue of $6.24 billion, signifying shifts of -8.03% and 0%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Organon. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Organon boasts a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Organon has a Forward P/E ratio of 1.84 right now. This indicates a discount in contrast to its industry's Forward P/E of 15.74.
It's also important to note that OGN currently trades at a PEG ratio of 1.43. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical Services industry currently had an average PEG ratio of 1.81 as of yesterday's close.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 159, this industry ranks in the bottom 36% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing
Organon (OGN - Free Report) closed the most recent trading day at $7.44, moving +2.76% from the previous trading session. This change outpaced the S&P 500's 0.64% gain on the day. Meanwhile, the Dow experienced a rise of 1.23%, and the technology-dominated Nasdaq saw an increase of 0.69%.
Heading into today, shares of the pharmaceutical company had gained 1.4% over the past month, outpacing the Medical sector's gain of 0.63% and the S&P 500's gain of 0.55%.
The investment community will be paying close attention to the earnings performance of Organon in its upcoming release. On that day, Organon is projected to report earnings of $0.74 per share, which would represent a year-over-year decline of 17.78%. Our most recent consensus estimate is calling for quarterly revenue of $1.53 billion, down 3.84% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.78 per share and a revenue of $6.24 billion, signifying shifts of -8.03% and 0%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Organon. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Organon boasts a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Organon has a Forward P/E ratio of 1.84 right now. This indicates a discount in contrast to its industry's Forward P/E of 15.74.
It's also important to note that OGN currently trades at a PEG ratio of 1.43. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical Services industry currently had an average PEG ratio of 1.81 as of yesterday's close.
The Medical Services industry is part of the Medical sector. With its current Zacks Industry Rank of 159, this industry ranks in the bottom 36% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.